Evidence map›Paper›PMID 34990778›Full record

Trial reportInternational journal of radiation oncology, biology, physics2022

Pre- and Posttherapy Risk Factors for Vasculopathy in Pediatric Patients With Craniopharyngioma Treated With Surgery and Proton Radiation Therapy.

John T Lucas, Austin M Faught, Chih Yang Hsu, Lydia J Wilson, Yian Guo, Yimei Li, Raja Khan, Jared B Becksfort, David A LeVine, Yousef Ismael and 8 more

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01419067 (A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01419067 phase2active not recruitingnot on this map

A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2011 to 2031Enrolled112ConditionsCraniopharyngiomaArmsRadical Surgery or Limited Surgery, Proton Therapy, ^1^8F-fluorodeoxyglucose, ^1^1C-methionine
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

John T LucasDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. Electronic address: john.lucas@stjude.org.
Austin M FaughtDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Chih Yang HsuGlaxoSmithKline, Exton, Pennsylvania.
Lydia J WilsonDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Yian GuoDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Yimei LiDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Raja KhanDepartment of Neurology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jared B BecksfortDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
David A LeVineUniversity of Tennessee Health Sciences Center, Memphis, Tennessee.
Yousef IsmaelDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Kaleb DarrowUniversity of Tennessee Health Sciences Center, Memphis, Tennessee.
Vadim P MoskvinDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Fakhriddin PirlepesovDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Paul KlimoSemmes Murphey Neurologic & Spine Institute, Memphis, Tennessee; Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee.
Lucas ElijovichDepartment of Neurology, University of Tennessee Health Sciences Center, Memphis, Tennessee; Semmes Murphey Neurologic & Spine Institute, Memphis, Tennessee; Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee.
Daniel J IndelicatoDepartment of Radiation Oncology, University of Florida, Jacksonville, Florida.
Fredrick A BoopSemmes Murphey Neurologic & Spine Institute, Memphis, Tennessee; Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee.
Thomas E MerchantDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
St. Jude Children's Research Hospital · USUniversity of Tennessee Health Science Center · USGlaxoSmithKline (United States) · USUniversity of Florida · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
PROFESSIONAL ONCOLOGY EDUCATION PROGRAMR25CA023944 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SUZANNE A. GRONEMEYER · 1986 to 2026
$8.3M
NCI NIH HHS P30 CA021765NCI NIH HHS R25 CA023944
6 · The paper itself

Abstract

purposeVasculopathy (VAS) is a significant complication associated with radiation therapy in patients treated for brain tumors. We studied the type, location, severity, timing, and resolution of VAS in children with craniopharyngioma treated with proton radiation therapy (PRT) and evaluated predictors of stenosis (STN) using a novel patient and imaging-based modeling approach. METHODS AND MATERIALS: Children with craniopharyngioma (n = 94) were treated with 54 Gy relative biological effectiveness PRT in a clinical trial, NCT01419067. We evaluated VAS type, location, severity, and resolution. VAS events were segmented and related to their location, operative corridor, PRT dose, and vascular territory to facilitate mixed effect logistic regression modeling of spatial predictors of STN events.

resultsForty-five (47.9%) patients had 111 instances of confirmed VAS (pre-PRT n = 37, 33.3%). The median time to post-PRT VAS was 3.41 years (95% confidence interval, 1.86-6.11). STN events were observed post-PRT in 23.4% (n = 22) of patients. Post-PRT VAS was detected by cerebral angiogram in 9.6% (n = 9), severe in 4.3% (n = 4), and compensated on perfusion in 2.1% (n = 2). Revascularization was required for 5 (5.3%) patients. Postsurgical, pre-PRT VAS, and PRT dose to unperturbed vessels were predictive of STN. The effect of PRT on STN was negligible within the surgical corridor.

conclusionsVAS often precedes PRT and was the strongest predictor of post-PRT STN. The adverse effect of PRT on STN was only apparent in unperturbed vasculature beyond the operative corridor.

Indexed as

CraniopharyngiomaPituitary NeoplasmsProton TherapyChildHumansProtonsRisk FactorsProtons

Identifiers

PMID34990778
PMCPMC9018579
OpenAlexW4206116083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.